Article Text

Download PDFPDF
Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor. Josef S Smolen

  • Contributors Conception and design: YohK. Analysis and interpretation of the data, critical revision for important intellectual content and final approval of the article: all authors. Obtaining of funding: YohK, NT, YosK, RY and HN. Collection and assembly: YohK.

  • Funding This report was supported by grants from the Japanese Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research JP19H03700 (to YohK), JP20K17428 (to NT), JP19K23847 and JP20K17446 (to YosK), JP19K08914 (to RY), JP20H03714 (to HN), JP16H06277 (to CoBiA).

  • Competing interests YohK reports personal fees from Amgen and grants from Chugai and Ono, outside the submitted work. No other authors report competing interests.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.